Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis

被引：0
|
作者：
Robert J. Fox
Rina Mehta
Timothy Pham
Julie Park
Kathleen Wilson
Machaon Bonafede
机构：
[1] Mellen Center for Multiple Sclerosis,
[2] Cleveland Clinic,undefined
[3] Bristol Myers Squibb,undefined
[4] IBM Watson Health,undefined
来源：
BMC Neurology | / 22卷
关键词：
Treatment pathway; Sankey diagram; Treatment patterns; Administrative claims database;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Disease-Modifying Therapy of Pediatric Multiple Sclerosis
    Tanuja Chitnis
    Neurotherapeutics, 2013, 10 : 89 - 96
  • [32] Disease-Modifying Therapy of Pediatric Multiple Sclerosis
    Chitnis, Tanuja
    NEUROTHERAPEUTICS, 2013, 10 (01) : 89 - 96
  • [33] Adherence to disease-modifying therapies among patients with multiple sclerosis in Bulgaria - A real world study
    Seitaridou, Yoana
    Chamova, Teodora
    Kamusheva, Maria
    PHARMACIA, 2024, 71 : 1 - 7
  • [34] Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis
    Halpern, Rachel
    Agarwal, Sonalee
    Dembek, Carole
    Borton, Leigh
    Lopez-Bresnahan, Maria
    PATIENT PREFERENCE AND ADHERENCE, 2011, 5 : 73 - 84
  • [35] Hospital admissions due to infections in the national population of people with multiple sclerosis on disease-modifying therapies: Real-world data from NHS England
    Garjani, Afagh
    Osborne, Nick
    Law, Graham
    Nightingale, Matthew
    Evangelou, Nikos
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 86 - 87
  • [36] Urinary Tract Infections in People with Multiple Sclerosis: A Real-World Administrative Claims Study
    Jordan, K. M.
    Hua, H.
    Edgeworth, M.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 242 - 242
  • [37] Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study
    Lita Araujo
    Svend S. Geertsen
    Allen Amedume
    Keiko Higuchi
    Janneke van Wingerden
    Neurology and Therapy, 2022, 11 : 1735 - 1748
  • [38] Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study
    Araujo, Lita
    Geertsen, Svend S.
    Amedume, Allen
    Higuchi, Keiko
    van Wingerden, Janneke
    NEUROLOGY AND THERAPY, 2022, 11 (04) : 1735 - 1748
  • [39] Real-world Effectiveness Of Initial Treatment With Newer Versus Injectable Disease-modifying Therapies In Pediatric Multiple Sclerosis
    Krysko, K. M.
    Graves, J. S.
    Rensel, M.
    Weinstock-Guttman, B.
    Rutatangwa, A.
    Aaen, G.
    Anita, B.
    Benson, L.
    Chitnis, T.
    Gorman, M.
    Goyal, M. S.
    Harris, Y.
    Krupp, L.
    Lotze, T.
    Mar, S.
    Moodley, M.
    Ness, J.
    Rodriguez, M.
    Rose, J.
    Schreiner, T.
    Tillema, J.
    Waltz, M.
    Casper, T.
    Waubant, E.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 46 - 47
  • [40] Real-world Effectiveness of Initial Treatment with Newer versus Injectable Disease-modifying Therapies in Pediatric Multiple Sclerosis
    Krysko, Kristen
    Graves, Jennifer
    Rensel, Mary
    Weinstock-Guttman, Bianca
    Rutatangwa, Alice
    Aaen, Gregory
    Belman, Anita
    Benson, Leslie
    Chitnis, Tanuja
    Gorman, Mark
    Goyal, Manu
    Harris, Yolanda
    Krupp, Lauren
    Lotze, Timothy
    Mar, Soe
    Moodley, Manikum
    Ness, Jayne
    Rodriguez, Moses
    Rose, John
    Schreiner, Teri
    Tillema, Jan-Mendelt
    Waltz, Michael
    Casper, T. Charles
    Waubant, Emmanuelle
    NEUROLOGY, 2020, 94 (15)
12345